
































Histone modifications often correlate with the state 
of gene expression 
The canonical nucleosome is a fundamental unit of 
chromatin and consists of a protein octamer of two 
molecules each of histone H2A, H2B, H3 and H4, 
wrapped by 147 bp of genomic DNA.  In this context, 
numerous histone post-translational modifications 
(PTMs) have been described that include acetylation, 
phosphorylation, methylation, ubiquitylation and 
SUMOylation [1]. Histone PTMs often correlate with 
the activity of the gene (or of a regulatory element such 
as an enhancer) that is in their proximity, suggesting a 
causal relationship. Relevant to the role of CBP/p300 as 
HATs, hyperacetylation of histone N-terminal tail 
lysines correlates strongly with active transcription [2]. 
Similarly, the recruitment of protein acetyltransferases 
positively correlates with histone hyperacetylation at 
active genes as shown by genome-wide chromatin 
immunoprecipitation (ChIP-Seq) studies of CBP and 
p300 in human T cells [3].  
 
 

































Practical difficulties hamper the in vivo analysis of 
histone mutations in mammals 
The function of histone PTMs in mammals remains 
uncertain because the multiple genes encoding each 
canonical histone, renders in vivo mutational analysis 
unfeasible in most instances. Exceptions to this 
limitation occur when analyzing histone variants that 
have few gene copies, or when assessing putative gain-
of function histone mutations, such as those identified 
in pediatric glioblastoma and glioma (e.g. H3.3 K27M) 
[4, 5]. For instance, knockout of the H2A variant 
H2A.Z reveals that it is required for early mouse 
development [6], whereas loss of another variant, 
macroH2A1, has subtle effects on mouse physiology 
and gene expression [7, 8].   The difficulty of testing  
histone point mutations in mammals has therefore 
contributed to the uncertainty of whether canonical 
histone PTMs are correlative with gene expression or 
causal. 
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for many histone PTMs 
In baker’s yeast, however, histone mutations can be 
easily made and numerous studies show that histone 
PTMs might not be as essential as their correlative 
behavior with transcription would suggest [9-14].  For 
instance, a systematic analysis of 486 different histone 
H3 and H4 mutations in yeast (where every residue was 
mutated at least one way) showed that only 11 of 79 N-
terminal tail deletions resulted in lethality, a phenotype 
that also depends to some extent on strain background 
[9]. (In the filamentous fungus Neurospora crassa, 
however, certain histone H3 mutants are not viable, 
such as K4L, K9L, K14R and K27L [15]).  Phenotype 
and gene expression changes are often surprisingly 
moderate or specific in yeast that harbor point mutations 
in the N-terminal tails of histones H2A, H2B, H3 and 
H4 [9, 16-19].  For example, simultaneously mutating 
eight modifiable H3 lysines (K4, K9, K14, K18, K23, 
K27, K36, and K79) to glycine has no effect on the 
growth rate of yeast in synthetic complete glucose 
medium [20].  Such results using yeast suggest that in 
mammals, histone PTMs might not always be essential 
for nearby gene expression and that gene-proximal 
recruitment of a histone-modifying enzyme might 
sometimes be correlative with transcription rather than 
causative. 
 
HATs and histone acetylation  
Controlled by the opposing actions of acetyltransferases 
(HATs) and deacetylases (HDACs), histone lysine 
acetylation is modeled to facilitate transcription by 
acting as a mark that affects the modification of other 
nearby residues, enhancing cofactor recruitment (e.g. 
via bromodomain containing proteins that bind acetyl-
lysine), and by relaxing DNA/histone interactions by 


















four main multi-gene families of mammalian HATs 
based on sequence similarity: GCN5 and PCAF 
(encoded by Gcn5l2 and Pcaf in mice), the MYST 
family (Htatip,  Myst1,  Myst2,  Myst3 and Myst4), the 
nuclear (or steroid) receptor coactivator family (Ncoa1, 
Ncoa2, Ncoa3, which may include Clock), and the CBP 
and p300 family (Crebbp and Ep300) [21]. While HATs 
within each family tend to share a high degree of 
sequence similarity, HAT enzymatic domain sequences 
are surprisingly dissimilar between the four main 
families [22, 23]. Such divergence between HAT 
families suggests that they evolved for functions distinct 
from acetylating histone lysine residues. Consistent 
with this idea, HATs are also called protein 
acetyltransferases (PATs), and are known to modify 
many other nuclear, cytoplasmic and mitochondrial 
proteins [24]. Consequently, HATs have been 
reclassified as KATs (lysine or K-acetyltransferases) to 
more accurately reflect their varied protein substrates 
[25]. 
 
CBP and p300 constitute the KAT3 family of HATs. 
CBP (CREBBP or CREB binding protein) and p300 
(EP300 or E1A binding protein p300) interact physically 
or functionally with over 400 different proteins and 
together form the two-member KAT3 family of histone 
acetyltransferases [21] (internet search “CBP-p300 
interactome” for an updated list with references). Their 
ability to interact with so many proteins occurs via 
several conserved protein binding domains [i.e., NRID, 
CH1 (TAZ1), KIX, Bromodomain, PHD, HAT, ZZ, 
TAZ2 and the NCBD (IBiD)] (Figure 1) [26, 27]. Most 
of these domains are unique to CBP and p300, at least at 
the level of primary sequence. The large repertoire of 
interacting partners makes CBP/p300 among the most 
heavily connected nodes in the known mammalian 





















domain  of  CREB  interacting  domain),  Bromodomain  (Br),  PHD  (plant  homeodomain),  HAT  (histone  acetyltransferase
domain), ZZ (ZZ‐type zinc finger domain), TAZ2  (transcriptional‐adaptor zinc‐finger domain 2; ZZ and TAZ2 together are
sometimes referred to as CH3 or cysteine/histidine‐rich region 3), and NCBD [nuclear coactivator binding domain or IRF3‐
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development 
Analysis of global transcription networks in model 
organisms indicates that proteins that function as nodes 
or “hubs” are often encoded by essential genes [28]. 
Consistent with designating CBP and p300 as “hubs,” 
they are each required for normal development and are 
implicated in human disease.  The archetype human 
disorder associated with a CBP or p300 mutation is 
Rubinstein-Taybi syndrome (RTS), a congenital 
developmental disorder characterized by growth 
impairment, mental retardation, and distinctive facial 
and skeletal anomalies [29]. The identification of 
heterozygous mutations of CBP provided the first 
evidence that RTS is caused by a deficiency in CBP 
protein function (i.e., haploinsufficiency) [30]. A 
subsequent screen of 92 RTS patients revealed that 36 
had mutations in CBP and three had mutations in p300 
[31]. In fact, several RTS-associated mutations have 
been found to affect CBP enzymatic activity, indicating 
that reduced HAT function could underlie the syndrome 
[32, 33]. However, at present the detailed molecular 
mechanisms that cause RTS are unknown. 
 
Nullizygous mutations of either CBP or p300 result 





+/- mice all die during 
embryogenesis, with the compound heterozygous 
phenotype indicating that the combined amount of the 
two proteins is limiting [34, 35]. Interestingly, CBP
+/- 
mice exhibit characteristics of RTS, including growth 
retardation and craniofacial anomalies [36, 37], 
implying that some of the developmental functions of 
CBP are conserved between mice and man [36-40]. In 
contrast,  p300
+/- mice are slightly smaller and less 
thrifty than wild-type littermate controls but are 
otherwise grossly normal [35].  
 
The early embryonic lethality observed in CBP and 
p300 knockout mice complicated efforts to understand 
the role of CBP and p300 in adult cell lineages. 
Subsequently, the creation of conditional Cre/LoxP 
knockout alleles (CBP
flox and p300
flox) has helped 
overcome this problem. Studies using conditional 
knockouts indicate that CBP and p300 individually can 
have distinct roles in defined cell lineages, although the 
loss of both genes is highly detrimental to cell 
proliferation [41-44].  
 
CBP and p300 mutations in cancer 
Several recent studies have identified somatic mutations 
that alter CBP and p300 activity in a significant fraction 
of patients with B-cell non-Hodgkin’s lymphoma [45-
47], relapsed acute lymphoblastic leukemia [48], and 
transitional cell carcinoma of the bladder [49]. These 
findings are consistent with the observation that RTS 
patients have an increased susceptibility for tumor 
development [50, 51].  
 
Are CBP and p300 counter-regulators of protein 
deacetylases in the control of aging and metabolism? 
Activation of sirtuin protein deacetylases is postulated 
to help mediate the effects of caloric restriction and 
reduced insulin signalling that promote longevity [52]. 
Presumably, HATs are the counter-regulators of sirtuin 
activity in this physiologically context through their 
ability to acetylate proteins that are targeted by HDACs.  
Although the role of HATs in the aging process is less 
well understood than it is for sirtuins, it is known that 
depleting CBP in C. elegans blocks the lifespan 
extension induced by dietary restriction and 
hypothalamic expression of CBP is reportedly reduced 
in aging mice [53]. Such studies suggest that CBP HAT 
activity is a determinant of healthy aging. In keeping 
with this notion, CBP
+/- mice are also lean and insulin-
sensitized [54] and growing evidence places CBP/p300 
in signalling pathways capable of promoting energy 
homeostasis [55, 56].  For example, p300 acetylates the 
energy-state-sensor AMP kinase to inhibit its activity 
and promote lipid storage; AMPK acetylation is 
counter-regulated by the deacetylase HDAC1, which 
promotes lipid breakdown [57]. Accordingly, CBP and 
p300 are receiving growing attention as potential 
therapeutic targets for the treatment of metabolic 
diseases and other age-related pathologies.  
 
CBP and p300 are important for whole animal 
energy homeostasis 
 During fasting, glucagon is secreted from the pancreas 
and promotes hepatic glucose production (HGP) by 
increasing liver intracellular cAMP and gluconeogenic 
gene expression [58]. Hepatic gluconeogenic gene 
transcription is stimulated via recruitment of HAT 
(CBP/p300) and non-HAT (CRTC, CREB Regulated 
Transcription Coactivator) coactivators to CREB that is 
bound to target gene promoters [59, 60].  However, 
fasting blood glucose levels and hepatic gluconeogenic 
gene expression are unaltered in CBP
KIX/KIX mice, which 
carry point mutations that block the interaction between 
the CBP KIX domain and CREB [61]. This indicates 
that the main interaction between CBP and CREB is not 
limiting for hepatic gluconeogenesis [60]. Conversely, 
mice with a serine-to-alanine mutation in the CH1 
domain of CBP (Ser436Ala) display increased HGP, 
and are resistant to the hypoglycemia-inducing effects 
of insulin and metformin [55, 62]. This implicates the 
CBP CH1 domain in glucose homeostasis, suggesting 
that Ser436 phosphorylation can negatively regulate the 
interaction between CBP and CREB. Moreover, as p300 
lacks a serine at the equivalent position in its CH1 
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unique insulin- and metformin-responsive properties 
and is limiting for liver gluconeogenesis [55, 62]. 
However, it was recently demonstrated that conditional 
knockout of CBP in the liver does not decrease fasting 
blood glucose or gluconeogenic gene expression in 
mice [56]. Similarly, fasting blood glucose levels, liver 
gluconeogenic gene expression and metformin 
responsiveness were all unaffected in mice homozygous 
for an in-frame deletion mutation in the CH1 domain of 
CBP (CBP
ΔCH1/ΔCH1) or p300 (p300
ΔCH1/ΔCH1) [56]. In 
fact, ΔCH1 mutant mice are lean and insulin-sensitized, 
suggesting that an intact CH1 domain structure is 
necessary for normal energy storage, but not the glucose 
lowering actions of insulin and metformin. Collectively, 
these findings are consistent with the notion that CBP is 
not limiting for hepatic gluconeogenesis, and that other 
coactivators can compensate for loss of CBP function at 
CREB target genes (e.g. p300, CRTC2).  
 
Insights from CBP and p300 hypomorphic 
mutations created in mice 
Several domains of CBP and p300 (e.g. CH1 and KIX) 
are interconnected by peptide sequences that are not 






























such domains can function independently. Studies of 
CBP/p300 individual domain knock-in mutations in 
mice support this idea. One example is the KIX domain 
that binds the transcription factors CREB and Myb.   
CREB is a key mediator of cAMP- and calcium-
inducible gene expression, and the signal-dependent 
phosphorylation of Ser133 of CREB is required for it to 
bind the KIX domain, which helps recruit CBP/p300 to 
target genes [63, 64]. CREB also recruits the non-HAT 
CRTC (previously called TORC) family of coactivators 
in signal-dependent manner to its bZIP domain (Figure 
2) [65, 66]. CBP and p300 KIX domain knockin 
mutations alter three surface residues that interact 
directly with CREB and Myb [61]. Indeed, CBP
KIX/KIX 
mice highlight the importance of this domain in CBP 
for learning and memory, which are CREB-mediated 
processes [67-69]. Analysis of p300
KIX/KIX mice revealed 
the relevance of the domain for hematopoiesis and the 
specific role of the Myb interaction with p300 KIX in 
controlling the production of megakaryocytes and 
platelets [61]. Independently, a forward genetic 
approach corroborated these findings by identifying a 
different mutation on the Myb-binding surface of p300 
KIX that also leads to increased platelets and 































Figure 2.  The  “coactivator‐poor  and  coactivator‐
rich” model showing that increased recruitment of 
distinct classes of coactivators (HATs CBP/p300, and 




curved  arrows  indicates  the  amount  of  different 
types (colored) of transactivating “biochemical flux”
that stimulate transcription. In certain endogenous 
promoter  contexts  the  increased  flux  though  one 
mechanism (e.g. CRTC) may overcome the lack of a
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primary mouse embryonic fibroblasts (MEFs) derived 
from KIX domain mutant mice has refined our 
understanding of endogenous CREB transactivation 
mechanisms. Surprisingly, while some cAMP-inducible 
genes (which are also CREB dependent) are highly 
sensitive to KIX mutation, others show only partial loss 
of activity or are unaffected [71]. This suggests that 
there are KIX domain-independent mechanisms that 
provide compensatory coactivation functions for CREB 
at certain target genes.  RNAi knockdown studies show 
that the non-HAT CREB coactivator CRTC can provide 
such redundancy for CBP/p300 [41]. Moreover, the 
overexpression of CRTC rescued the expression of 
some (but not all) CREB target genes that are dependent 
on the KIX domain or holo-CBP/p300 [41, 71].  
 
Interestingly, similar observations were observed from 
the study of hypoxia-responsive gene expression in 
MEFs deficient for both CBP and p300 CH1 domain 
function [72, 73]. While the CH1 domain is critical for 
efficient recruitment of CBP/p300 to hypoxia-inducible 
factor (HIF) target genes and appears to contribute to an 
average of 35-50 percent of hypoxia-responsive gene 
expression, not all genes were equally sensitive to the 
CH1 mutation. Collectively, these findings indicate that 
individual endogenous CREB- and HIF-target genes 
differentially use multiple and partially redundant 
coactivator mechanisms for their expression in response 
to cAMP and hypoxia, respectively. 
 
CBP and p300 double knockout fibroblasts  
Until recently, the general consensus has been that some 
CBP or p300 protein is required for cell viability or 
proliferation. For example, RNA interference (RNAi) 
mediated knockdown of dCBP in Drosophila Kc cells 
[74], and CBP and p300 in immortal HeLa cells [75], 
results in cell death because of chromosome shredding 
and mitotic catastrophe. Similarly, B and T cells lacking 
both CBP and p300 cannot be generated in mice, 
although lymphocytes that lack one or the other 
coactivator are viable [42-44, 76]. In contrast, 
fibroblasts that are deficient for both CBP and p300 
(double knockout or dKO MEFs) can be generated 
through the use of Cre/LoxP conditional knockout 
alleles [41]. Although dKO MEFs cannot proliferate, 
they are viable for weeks in culture, permitting the first 
assessment of transcription and histone acetylation after 
stable inactivation of a major family of HAT proteins.  
 
A non-HAT coactivator can provide context-
dependent redundancy for CBP/p300 
Initial experiments using CBP/p300 dKO MEFs focused 
on cAMP-responsive transcription. Interestingly, 
despite histone H4 acetylation being attenuated at 
CREB target gene promoters in response to cAMP, 
transcription was not uniformly inhibited in dKO MEFs 
[41]. Perhaps most surprising was the finding that the 
cAMP-inducible expression of several CREB target 
genes was actually increased in dKO MEFs. Why there 
are these contrasting effects of CBP/p300 loss on 
different cAMP-inducible genes is not clear, but there 
must be compensatory or redundant mechanisms that 
are differentially required for individual target genes 
[21]. Another acetyltransferase would be a logical 
candidate to provide redundancy, but the acetylation of 
certain histone residues was deficient even at target 
genes that were expressed strongly in the absence of 
CBP/p300 [41]. Instead, the non-HAT coactivators 
CRTC1 and CRTC2 appear to dampen the effect of 
losing CBP/p300 as their expression is increased in 
dKO MEF, and overexpression of CRTC2 can rescue 
the expression of certain CBP/p300-dependent CREB 
target genes [41, 71]. Consistent with this idea, RNAi-
mediated knockdown of CRTC in dKO MEFs reduces 
the expression of CBP/p300-independent genes, 
indicating that this non-HAT provides redundancy for 
CBP/p300 for at least some CREB targets [41].  
 
CBP and p300 account for nearly all H3K18 and 
H3K27 acetylation in fibroblasts 
The effect of CBP/p300 loss on the expression of 
individual CREB target genes is not uniform in dKO 
MEFs, even though the cells have lost at least 90 
percent of global histone H3K18 and H3K27 
acetylation [41, 77].  These mutant MEFs also have 
reduced promoter localized H4 hyperacetylation in 
response to cAMP [41]. The loss of H3K27ac is striking 
because this modification has been shown by others to 
correlate with active transcription and can be used to 
distinguish active enhancers from those that are inactive 
or poised [78-81]. Because many genes in dKO MEFs 
show only a partial loss of expression, or sometimes 
none at all, this raises questions of how, when, and 
where H3K18ac and H3K27ac are critical for 
stimulating transcription. Indeed, Valor et al. also noted 
that the loss of CBP in the forebrain neurons of adult 
mice dramatically reduces histone acetylation but only 
mildly effects transcription and cell viability [82]. 
 
A “coactivator rich vs. coactivator poor” model for 
endogenous CREB targets 
Curiously, increased levels of promoter-localized 
histone acetylation and CBP/p300 recruitment in wild 
type MEFs tend to inversely correlate (albeit 
imperfectly) with the extent to which a CREB target 
gene is dependent on CBP/p300 for transcription [41]. 
Broadly, this suggests that the importance of CBP/p300 
for the transcription of a particular target gene correlates 
better with the low to moderate levels of recruitment of 
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implications for interpreting genome-wide mapping 
studies such as ChIP-Seq, where stronger signals for a 
cofactor or histone modification may be interpreted to 
indicate functional importance.  
 
DNA sequence may dictate coactivator mechanisms 
employed by any individual gene 
The critical characteristics that determine the extent to 
which an endogenous CREB target gene requires 
CBP/p300 are not completely clear, although the 
number of CREB binding sites may be one determining 
feature [41]. (This correlate does not appear to apply to 
plasmid reporter genes, however). Recent studies of 
toll-like-receptor-responsive gene expression in 
macrophages suggest that promoter DNA sequences 
that are rich in GC-content or CpG-dinucleotides might 
be able to overcome the need for certain types of 
coactivators [83, 84].  However, the GC and CpG 
content of CREB target gene promoters does not 
correlate very well with their dependence on CBP/p300 
for expression [41]. 
 
Does a “coactivator rich vs. coactivator poor” model 
apply to other CBP/p300-dependent transcription 
factors and signalling pathways?  
Evidence so far indicates that CBP and p300 are 
variably uniformly required for the function of other 
transcription factors besides CREB. For example, 
studies using dKO MEFs indicate that CBP and p300 
are dispensable for transactivation of the p53 target 
genes, p21 and Mdm2 [85]. On the other hand, retinoic 
acid-inducible gene expression tends to be uniformly 
dependent on CBP/p300, whereas double-stranded-
RNA- and serum-inducible genes show non-uniform 
requirements for CBP/p300 [85]. Thus it appears that 
the requirement for CBP/p300-mediated coactivation is 
context-specific for a variety of endogenous target 
genes driven by distinct transcription factors.  Whether 
CBP/p300-independent target genes are generally 




Increasingly, models of transcriptional coactivation 
derived from reductionist approaches do not appear to 
be universally applicable on a genomic scale. Data 
shows that CBP/p300 are recruited to many genes 
where they are only partly (or not all) required for 
stimulating transcription. A useful analogy to describe 
this phenomenon is to compare a DNA-binding 
transcription factor (e.g. CREB) to a plumber or 
handyman that takes a toolbox (i.e. coactivators such as 
CBP/p300 and CRTC) to all job sites (target genes), but 
it is the nature of the problem to be “fixed” that 
determines which tools are required at each jobsite. In 
this scenario, the occurrence of a cofactor at a particular 
locus as determined by methods such as ChIP-Seq is not 
indicative of function, but only suggestive. Similarly for 
histone modifications, loss of CBP and p300 strongly 
attenuates certain histone acetylation marks, notably 
H3K18ac and H3k27ac, but gene expression is not 
necessarily reduced to the same extent.  Given that 
histone point mutations often have a modest effect in 
yeast, and that the effects of histone mutations in 
mammals are largely unknown, it seems reasonable to 
wonder if histone acetylation is the most important 
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